It has been shown that the drug Rimonabant (Acomplia) a selective cannabinoid receptor blocker (CB1), can help obese patients keep weight off . Supplementation with 20 milligrams of rimonabant a day resulted in a significant decrease in body weight and waist circumference -- a marker of cardiovascularly dangerous visceral fat. It also improved HDL (good) cholesterol, triglycerides, and the prevalence of metabolic syndrome in overweight/obese patients.
The drug also exhibited similar results at the end of two years study and patients lost and kept off an average of 8.5 kilograms, or about 19 pounds. That translates to a 5-percent to 10-percent percent weight-loss for patients. For each kilogram, there was also a one-centimeter reduction in waistline. It was also proven to improve insulin sensitivity, which is a risk factor for cardiovascular disease, and increase patients' HDL cholesterol by 28 percent.
